A review of alpha-1 antitrypsin deficiency

Seminars in Respiratory and Critical Care Medicine

Volumn 26, Issue 2, 2005, Pages 154-166

  Ranes, Justin ^a   Stoller, James K ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Alpha 1 antitrypsin; Chronic obstructive pulmonary disease; Emphysema; Genetic disorders

Indexed keywords

ALPHA 1 ANTITRYPSIN; BRONCHODILATING AGENT; DESMOSINE; ELASTIN; ZEMAIRA;

ALLELISM; ALPHA 1 ANTITRYPSIN DEFICIENCY; ANCA ASSOCIATED VASCULITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; EMPHYSEMA; FORCED EXPIRATORY VOLUME; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; LIFESPAN; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LUNG FUNCTION; NONHUMAN; PANNICULITIS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SMOKING HABIT; SPIROMETRY; SURVIVAL; WEGENER GRANULOMATOSIS;

AIRWAY RESISTANCE; ALLELES; ALPHA 1-ANTITRYPSIN; ALPHA 1-ANTITRYPSIN DEFICIENCY; COMBINED MODALITY THERAPY; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; RESPIRATORY FUNCTION TESTS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 18144430936     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-869536     Document Type: Review

References (52)

1. Laurell CB, Eriksson S. The electrophoretic alpha 1-globulin pattern of serum in alpha 1-antitrypsin deficiency. Scand J Clin And Lab Investigation 1963;15:132-140
2. Brantly M, Nukiwa T, Crystal RG. Molecular basis of alpha 1-antitrypsin deficiency. Am J Med 1988;84:13-27
3. DeMeo DL, Silverman EK. Genetic aspects of alpha 1-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004;59:259-264
4. Harten S, Stoller JK, Younossi Z. Alpha 1-antitrypsin deficiency. In: Al Knawy B, Shiffman M, Wiesner R, eds. Hepatology: A Practical Approach. 1st ed. Elsevier Science BV. In press
5. American Thoracic Society/European Respiratory Society Statement. Standards for the diagnosis and management of individuals with alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 2003;168:818-900
6. Wiedemann HP, Stoller JK. Lung disease due to alpha 1-antitrypsin deficiency. Curr Opin Pulm Med 1996;2:155-160
7. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung, and Blood Institute Registry of Alpha 1-antitrypsin Deficiency. Chest 1997;111:394-403
8. de Serres FJ. Worldwide racial and ethnic distribution of alpha 1-antitrypsin deficiency. Chest 2002;122:1818-1829
9. Sveger T. Liver disease in alpha 1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976;294:1316-1321
10. O'Brien ML, Buist NRM, Murphy WH. Neonatal screening for alpha 1-antitrypsin deficiency. J Pediatr 1978;92:1006
11. Silverman EK, Miletich JP, Pierce JA, et al. Alpha 1-antitrypsin deficiency: high prevalence in the St. Louis area determined by direct population screening. Am Rev Respir Dis 1989;140:961
12. Spence WC, Morris JE, Pass K, Murphy PD. Molecular confirmation of alpha 1-antitrypsin genotypes in newborn dried blood specimens. Biochem Med Metab Biol 1993;50:233-240
13. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med 1994;61:461-467
14. Ogushi F, Fells GA, Hubbard RC, et al. Z-type alpha1-antitrypsin is less competent than M1-type alpha-1 anti-trypsin as an inhibitor of neutrophil elastase. J Clin Invest 1987;80:1366-1374
15. Ad hoc Committee of the ATS Board of Directors. Guidelines for the approach to the patient with severe hereditary alpha-1-antitrypsin deficiency. American Thoracic Society. Am Rev Respir Dis 1989;140:1494-1497
16. Carrell RW, Lomas DA. Alpha 1-antitrypsin deficiency: a model for conformational diseases. N Engl J Med 2002;346:45-52
17. Lomas DA. Loop-sheet polymerization: the mechanism of alpha 1-antitrypsin deficiency. Respir Med 2000;94:S3-S6
18. Elliott PR, Bilton D, Lomas DA. Lung polymers in Z alpha 1-antitrypsin deficiency-related emphysema. Am J Respir Cell Mol Biol 1998;18:670-674
19. Jasvir S, Parmar RM, Reed BJ, et al. Polymers of α1-antitrypsin are chemotactic for human neutrophils. A new paradigm for the pathogenesis of emphysema. Am J Respir Cell Mol Biol 26:723-730
20. Silverman EK, Pierce JA, Province MA, et al. Variability of pulmonary function in alpha 1-antitrypsin deficiency: clinical correlates. Ann Intern Med 1989;111:982-991
21. Sanford AJ, Silverman EK. Chronic obstructive pulmonary disease: susceptibility factors for COPD the genotype-environment interaction. Thorax 2002;57:736-741
22. Lomas DA, Evans DL, Finch JT, Carrell RW. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature 1992;357:605-607
23. Janus ED, Phillips NT, Carrell RW. Smoking, lung function, and alpha 1-antitrypsin deficiency. Lancet 1985;19:152-154
24. Gishen P, Saunders AJ, Tobin MJ, Hutchison DC. Alpha 1-antitrypsin deficiency: The radiological features of pulmonary emphysema in subjects of Pi type Z and Pi type SZ: a survey by the British Thoracic Association. Clin Radiol 1982;33:371-377
25. McBean J, Sable A, Maude J, Robinson-Bostom L. Alpha 1-antitrypsin deficiency panniculitis. Cutis 2003;71:205-209
26. Guest PJ, Hansell DM. High resolution computed tomography (HRCT) in emphysema associated with alpha 1-antitrypsin deficiency. Clin Radiol 1992;122:254-257
27. Cuvelier A, Muir JF, Hellot MF, et al. Distribution of alpha 1-antitrypsin alleles in patients with bronchiectasis. Chest 2000;117:415-419
28. Eden E, Hammel J, Rouhani F, et al. Asthma features in severe alpha 1-antitrypsin deficiency: experience of the National Heart, Lung, and Blood Institute Registry. Chest 2003;123:765-771
29. Fallat RJ. Reactive airways disease and alpha1-antitrypsin deficiency. In: Crystal RG, ed. Alpha 1-Antitrypsin Deficiency. New York, NY: Marcel Dekker; 1996
30. Piitulainen E, Sveger T. Respiratory symptoms and lung function in young adults with severe alpha 1-antitrypsin deficiency (PiZZ). Thorax 2002;57:705-708
31. Wall M, Moe E, Eisenberg J, et al. Long-term follow-up of a cohort of children with alpha 1-antitrypsin deficiency. J Pediatr 1990;116:248-251
32. Wall M, Moe E, Eisenberg J, et al. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr 1990;116:248-251
33. Hutchison DC, Tobin MJ, Cooper D, Lowe D. Longitudinal studies in alpha 1-antitrypsin deficiency: a survey by the British Thoracic Society. In: Taylor JC, Mittman C, eds. Pulmonary Emphysema and Proteolysis. Orlando: Academic Press; 1987
34. Wu MC, Eriksson S. Lung function, smoking and survival in severe alpha 1-antitrypsin deficiency, Pi*ZZ. J Clin Epidemiol 1988;41:1157-1165
35. Seersholm N, Kok-Jensen A. Survival in relation to lung function and smoking cessation in patients with severe hereditary alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 1995;151:369-373
36. 1 in patients with severe hereditary alpha 1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997;10:2260-2263
37. 1 decline in individuals with severe deficiency of alpha 1-antitrypsin. Am J Respir Crit Care Med 1998;158:49-59
38. 1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J 1999;13:247-251
39. Mayer AS, Stoller JK, Bartelson BB. Occupational exposure risk in individuals with PI*Z alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 2000;162:553-558
40. 1 decline in individuals with severe deficiency of alpha 1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998;158:49-59
41. Seersholm N, Kok-Jensen A, Dirksen A. Survival of patients with severe alpha 1-antitrypsin deficiency with special reference to non-index cases. Thorax 1994;49:695-698
42. Alpha-1 Antitrypsin Deficiency Study Group. Prepared by Stoller JK, Schluchter MD. Cause-specific mortality in the NHLBI Registry for Patients with Deficiency of Alpha-1 Antitryspin [abstract]. Am J Respir Crit Care Med 1998;157:A18
43. Eriksson S. Alpha 1-antitrypsin deficiency: natural course and therapeutic strategies. In: Boyer J, Blum HE, Maier KP, Sauerbruch T, Stalder GA, eds. Cirrhosis and Its Development. Falk Symposium 115. Dordrecht: Kluwer Academic; 2000:307-315
44. Stoller JK. Augmentation therapy for severe alpha 1-antitrypsin deficiency: is the jury still out on a trial? Thorax 1998;53:1007-1009
45. Wewers MD, Casolaro MA, Sellers SE, et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N Engl J Med 1987;316:1055-1062
46. Stone PJ, Morris TA III, Franzblau C, Snider GL. Preliminary evidence that augmentation therapy diminishes degradation of cross-linked elastin in alpha 1-antitrypsin-deficient humans. Respiration 1995;62:76-79
47. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha 1-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999;160:1468-1472
48. Gottlieb DJ, Luisetti M, Stone PJ, et al. Short-term supplementation therapy does not affect elastin degradation in severe alpha 1-antitrypsin deficiency. The American-Italian AATD Study Group. Am J Respir Crit Care Med 2000;162:2069-2072
49. Lieberman J. Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: a new hypothesis with supporting data. Chest 2000;118:1480-1485
50. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha 1-protease inhibitor deficiency before and during therapy with IV alpha 1-protease inhibitor. Chest 2001;119:737-744
51. Stockley RA, Bayley DL, Unsal I, Dowson LJ. The effect of augmentation therapy on bronchial inflammation in alpha 1-antitrypsin deficiency. Am J Respir Crit Care Med 2002;165:1494-1498
52. Stoller JK, Fallat R, Schluchter MD, et al. Augmentation therapy with alpha 1-antitrypsin: patterns of use and adverse events. Chest 2003;123:1425-1434